| Date | Acquired company | Acquiring company | Amount | Related |
|---|---|---|---|---|
| 2014-05-12 | Lumena Pharmaceuticals (USA) | Shire (UK - USA) | $260 million in cash, plus a payment for net cash at closing, and near-term contingent milestone payments related to ongoing clinical trials | Rare diseases Orphan drugs |
| 2014-05-09 | Novafarma Indústria Farmacêutica (Brazil) | Fresenius Kabi (Germany) | undisclosed | |
| 2014-05-08 | Chelsea Therapeutics (USA) | Lundbeck (Denmark) | $ 658 million (approximately DKK 3.54 billion - €470.5 million) | CNS diseases |
| 2014-05-02 | Fibrotech Therapeutics (Australia) | Shire (UK - USA) | $75 million and certain contingent payments | Rare diseases |
| 2014-05-01 | Harlan Laboratories (USA) | Huntingdon Life Sciences (UK) | undisclosed | contract research services |
| 2014-04-23 | GSK oncology assets (UK) | Novartis (Switzerland) | $ 14.5 billion payment and up to $ 1.5 billion contingent on a development milestone | Cancer - Oncology Infectious diseases OTC |
| 2014-04-22 | Novartis Consumer Healthcare, Vaccines and Oncology businesses (Switzerland) | GSK (UK) | $ 7.1 billion plus royalties | Cancer - Oncology OTC Vaccines |
| 2014-04-22 | Novartis Animal Health (Switzerland) | Eli Lilly (USA - IN) | $ 5.4 billion | |
| 2014-04-21 | Sanofi's Cell Therapy and Regenerative Medicine (CTRM) business | Aastrom Biosciences (USA) | $6.5 million | regenerative medicine cell therapy |
| 2014-04-16 | Topotarget (Denmark) | BioAlliance Pharma (France) | Cancer - Oncology Orphan drugs |
|
| 2014-04-07 | IQuum (USA) | Roche (Switzerland) | up to $ 450 million (€324 million) | molecular diagnostic point of care diagnostic |
| 2014-04-07 | Questcor Pharmaceuticals (USA) | Mallinckrodt Pharmaceuticals (Ireland) | $5.6 Billion | specialty pharmaceuticals |
| 2014-03-31 | Aptiv Solutions (USA) | Icon (Ireland) | $143.5 million | CRO |
| 2014-03-24 | Bionamics (Germany) | Evotec (Germany) | undisclosed | Technology - Services CRO |
| 2014-03-19 | Vidara Therapeutics International (USA - Ireland) | Horizon Pharma (USA) | $660 million (€435.5 million) | specialty pharma |
| 2014-03-13 | Activaero (Germany) | Vectura (UK) | €130 million | Respiratory diseases |
| 2014-03-13 | Galapagos’ Argenta and BioFocus service operations (Belgium - UK) | Charles River Laboratories (USA) | up to €134 million | life science services |
| 2014-03-04 | Cytocell (UK) | Oxford Gene Technology (UK) | undisclosed | |
| 2014-02-21 | Cangene (Canada) | Emergent BioSolutions (USA - MD) | $222 million | |
| 2014-02-18 | Forest Laboratories (USA - NJ) | Actavis (Ireland) | $25 billion |
